Hologic, Inc. (HOLX)
| Market Cap | 18.55B |
| Revenue (ttm) | 4.54B |
| Net Income (ttm) | 1.38B |
| Shares Out | 258.61M |
| EPS (ttm) | 5.27 |
| PE Ratio | 13.67 |
| Forward PE | 8.59 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $71.97 |
| Previous Close | $74.82 |
| Change ($) | -2.85 |
| Change (%) | -3.81% |
| Day's Open | 74.60 |
| Day's Range | 71.72 - 75.05 |
| Day's Volume | 1,372,696 |
| 52-Week Range | 26.49 - 85.00 |
Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #acquisition--Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.
Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.
Top Ranked Growth Stocks to Buy for February 11th
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #holx--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Top Ranked Growth Stocks to Buy for February 9th
Skyworks (SWKS), Hologic (HOLX), II-VI (IIVI) and MaxLinear (MXL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.
Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be over by summer 2021 but a long-term war that will be waged for many year...
Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank. These are: AAPl, F, FDX, HOLX, WY.
DCP Midstream (DCP), TEGNA (TGNA), Hologic (HOLX), Crocs (CROX) and Skyworks Solutions (SWKS) are five stocks with explosive relative price strength.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ESG--Hologic's New Sustainability Report Highlights How the Company's Purpose-Driven Culture is Making a Unique Difference in the World
Hologic CEO says Covid-19 testing ramp up has given the company a leg up for future business
Steve Macmillan, chief executive of the diagnostic equipment manufacturer, explained why the business trajectory for Hologic will be even stronger for the company post pandemic.
"We've clearly gotten a big bump up from our Covid testing," Hologic CEO Steve Macmillan said in a "Mad Money" interview.
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Top Ranked Growth Stocks to Buy for February 3rd
Solid Companies for Investors Interested in Medical Stocks and Big Boats.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities
Top Ranked Growth Stocks to Buy for February 1st
Is (HOLX) Outperforming Other Medical Stocks This Year?
Hologic (HOLX) possesses solid growth attributes, which could help it handily outperform the market.
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
At this stage, it will be prudent to invest in large-cap stocks that have strong growth potential for 2021. These are: FDX, F, HOLX, MOS and LEN.
Hologic, Inc. (HOLX) CEO Steve MacMillan on Q1 2021 Results - Earnings Call Transcript
Hologic (HOLX) delivered earnings and revenue surprises of 33.64% and 0.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Hologic (NASDAQ:HOLX) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 368.85% year over year to $2.86, which b...
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2021
Top Ranked Growth Stocks to Buy for January 27th
Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.
Top Ranked Growth Stocks to Buy for January 21st
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.
In the latest trading session, Hologic (HOLX) closed at $77.22, marking a +1.62% move from the previous day.
Hologic (HOLX), SolarEdge Technologies (SEDG) and XPO Logistics (XPO) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.
In the latest trading session, Hologic (HOLX) closed at $76.48, marking a -1.76% move from the previous day.
Top Ranked Growth Stocks to Buy for January 14th
Is (HOLX) Outperforming Other Medical Stocks This Year?
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Hologic (HOLX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.
The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.
Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.
Shares of Hologic Inc. are up 5% in premarket trading Friday after the medical technology company posted preliminary revenue figures ahead of the consensus forecast. The company expects to rep...
About HOLX
Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SA... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 21, 1990 |
| CEO Stephen MacMillan | Employees 5,814 |
| Stock Exchange NASDAQ | Ticker Symbol HOLX |
Analyst Forecasts
According to 16 analysts, the average rating for Hologic stock is "Buy." The 12-month stock price forecast is 89.08, which is an increase of 23.77% from the latest price.